Neumora Therapeutics, Inc. (NMRA) intrinsic value & 10-year financials
Neumora Therapeutics, Inc. (NMRA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.47
- Market cap
- $77.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -208.8%
- Free cash flow (FY2025)
- —
NMRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$236.9M | -$1.45 | — | — | -668.7% |
| FY2024 | — | -$243.8M | -$1.53 | — | — | -271.9% |
| FY2023 | — | -$235.9M | -$3.63 | -$163.4M | — | 86.1% |
| FY2022 | — | -$130.9M | -$4.81 | -$115.4M | — | 19.2% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Neumora Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Neumora Therapeutics, Inc. has earned high returns on invested capital, averaging 24.0% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Neumora Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Neumora Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.